NR4A1 and invasive ductal breast carcinoma: ICE3, a recently completed prospective, multicenter trial found that hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative invasive ductal carcinomas (IDC) treated with cryoablation had a decreased 5-year overall recurrence compared to surgical resection.